Biogen, a multinational biotechnology company, and Eisai, a Japanese pharmaceutical company, are planning to file for Food and Drug Administration (FDA) approval for an Alzheimer’s drug that had mixed results in clinical trials. Can this controversial medication offer fresh hope to millions of people worldwide?